Literature DB >> 17516624

Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population.

Till Uhlig1, Jon H Loge, Ivar S Kristiansen, Tore K Kvien.   

Abstract

OBJECTIVE: To compare levels of health-related quality of life (HRQOL) among patients with rheumatoid arthritis (RA) to those of the general population.
METHODS: Disease burden was assessed using a generic health status instrument (Medical Outcome Study Short Form-36) for measurements of HRQOL and SF-6D to calculate utility scores in representative patients aged 20 to 79 years from the Oslo RA Register (n = 1052), and in individuals in the general population (n = 2323). Comparisons were performed with respect to sex and age, and standardized difference scores (s-scores) were calculated for comparisons with the norm.
RESULTS: HRQOL in patients with RA was reduced compared to the general population on all scales of the SF-36 for both males and females and for all age groups. s-scores adjusted for age and education ranged from -1.39 for physical functioning to -0.27 for mental health. The overall difference in utility was 0.16 and ranged from 0.13 (in female patients below 50 yrs) to 0.20 (patients 50-60 years). This implies that RA of 1 year duration entails a disease burden of 14-20 quality-adjusted life-years in 100 RA patients.
CONCLUSION: RA inflicts a substantial disease burden, and the disease affects all HRQOL dimensions as measured by the SF-36 in both sexes and in all age groups. Physical functioning is predominantly affected, but RA has social and mental consequences.

Entities:  

Mesh:

Year:  2007        PMID: 17516624

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  30 in total

1.  The burden of disease in rheumatoid arthritis.

Authors:  Till Uhlig; Rikke H Moe; Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

Review 2.  Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Authors:  Anthony S Russell; Wojtek P Olszynski; K S Davison; Cheryl Koehn; Boulos Haraoui
Journal:  Clin Rheumatol       Date:  2009-12-29       Impact factor: 2.980

3.  Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.

Authors:  Javeria Ali Hashmi; Kiran Yashpal; David W Holdsworth; James L Henry
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

4.  Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.

Authors:  Katrine Løppenthin; Bente Appel Esbensen; Mikkel Østergaard; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  Clin Rheumatol       Date:  2016-10-25       Impact factor: 2.980

5.  [Health economic aspects of a stratified medicine for rheumatoid arthritis].

Authors:  M Frank; T Mittendorf
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

6.  Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis.

Authors:  Kjersti Grønning; Erik Rødevand; Aslak Steinsbekk
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

7.  Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.

Authors:  T Beukelman; K G Saag; J R Curtis; M L Kilgore; M Pisu
Journal:  Osteoporos Int       Date:  2009-11-24       Impact factor: 4.507

8.  Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5 years of duration.

Authors:  Chalotte Heinsvig Poulsen; Søren Jacobsen; Morten Frisch; Kirsten Frederiksen; Christoffer Johansen
Journal:  Rheumatol Int       Date:  2013-06-29       Impact factor: 2.631

9.  Implications of long-term conditions for both mental and physical health: comparison of rheumatoid arthritis and schizophrenia.

Authors:  Heidi Lempp; Graham Thornicroft; Morven Leese; Naomi Fearns; Helen Graves; Bernadette Khoshaba; Antonio Lasalvia; David Scott; Michele Tansella
Journal:  Qual Life Res       Date:  2009-05-10       Impact factor: 4.147

10.  Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases.

Authors:  Vivek Nagaraja; Constance Mara; Puja P Khanna; Rajaie Namas; Amber Young; David A Fox; Timothy Laing; William J McCune; Carol Dodge; Debra Rizzo; Maha Almackenzie; Dinesh Khanna
Journal:  Qual Life Res       Date:  2017-10-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.